Carbonic anhydrase 9 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Carbonic anhydrase 9 shows late clinical disease relevance led by renal cell carcinoma. 3 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q16790. Start with renal cell carcinoma, then reuse UniProt Q16790 as the stable protein anchor across project notes and exports.
Start with renal cell carcinoma, then reuse UniProt Q16790 as the stable protein anchor across project notes and exports.
Carbonic anhydrase 9 shows late clinical disease relevance led by renal cell carcinoma. 3 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.
Start review with renal cell carcinoma because it currently carries late clinical support. Linked drugs include CG250 111IN, CG250 177LU, GIRENTUXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCarbonic anhydrase 9
Review this target as Carbonic anhydrase 9, mapped to UniProt Q16790. Sequence length is 459 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Carbonic anhydrase 9 as ChEMBL target CHEMBL3594, mapped to UniProt Q16790. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Carbonic anhydrase 9 is the right protein anchor across sources, using UniProt Q16790 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why renal cell carcinoma is currently framed as late clinical support. It currently carries 3 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Carbonic anhydrase 9 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q16790 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Carbonic anhydrase 9 |
| UniProt Accession | Q16790 |
| Component Type | Protein |
| Sequence Length | 459 aa |
Carbonic anhydrase 9
Review this target as Carbonic anhydrase 9, mapped to UniProt Q16790. Sequence length is 459 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Carbonic anhydrase 9 shows late clinical disease relevance led by renal cell carcinoma. 3 more disease programs remain visible in the same review block.
Start review with renal cell carcinoma because it currently carries late clinical support. Linked drugs include CG250 111IN, CG250 177LU, GIRENTUXIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4583164 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4573963 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4565560 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4558287 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4553519 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4551069 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4543024 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4456851 | 11.0 | Kd | 0.01 | Preclinical |
| CHEMBL4176828 | 10.96 | Kd | 0.011 | Preclinical |
| CHEMBL4174214 | 10.96 | Kd | 0.011 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 631 | 5,586 | 7.1 |
| assay format | 50 | 420 | 7.7 |
| cell-based format | 37 | 47 | 7.8 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 3 | 33 | 7.1 |
| assay format | 2 | 20 | 7.5 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 17 | 7.4 |